LOGC Stock Overview
LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.70|
|52 Week High||US$9.75|
|52 Week Low||US$1.69|
|1 Month Change||-31.17%|
|3 Month Change||-55.50%|
|1 Year Change||-81.26%|
|3 Year Change||-79.76%|
|5 Year Change||n/a|
|Change since IPO||-85.22%|
Recent News & Updates
Is LogicBio Therapeutics (NASDAQ:LOGC) Weighed On By Its Debt Load?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Does LogicBio Therapeutics (NASDAQ:LOGC) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
|LOGC||US Biotechs||US Market|
Return vs Industry: LOGC underperformed the US Biotechs industry which returned -22% over the past year.
Return vs Market: LOGC underperformed the US Market which returned 4.2% over the past year.
|LOGC Average Weekly Movement||10.1%|
|Biotechs Industry Average Movement||10.2%|
|Market Average Movement||6.7%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: LOGC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: LOGC's weekly volatility (10%) has been stable over the past year.
About the Company
LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. The company’s lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia.
LogicBio Therapeutics Fundamentals Summary
|LOGC fundamental statistics|
Is LOGC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|LOGC income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-1.15|
|Net Profit Margin||-964.74%|
How did LOGC perform over the long term?See historical performance and comparison
Is LogicBio Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: LOGC ($1.7) is trading below our estimate of fair value ($6.5)
Significantly Below Fair Value: LOGC is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: LOGC is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: LOGC is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate LOGC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: LOGC is good value based on its PB Ratio (1.4x) compared to the US Biotechs industry average (1.9x).
How is LogicBio Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LOGC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: LOGC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: LOGC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: LOGC's revenue (47% per year) is forecast to grow faster than the US market (9.1% per year).
High Growth Revenue: LOGC's revenue (47% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if LOGC's Return on Equity is forecast to be high in 3 years time
How has LogicBio Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: LOGC is currently unprofitable.
Growing Profit Margin: LOGC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: LOGC is unprofitable, and losses have increased over the past 5 years at a rate of 32% per year.
Accelerating Growth: Unable to compare LOGC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LOGC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).
Return on Equity
High ROE: LOGC has a negative Return on Equity (-97.68%), as it is currently unprofitable.
How is LogicBio Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: LOGC's short term assets ($60.7M) exceed its short term liabilities ($13.7M).
Long Term Liabilities: LOGC's short term assets ($60.7M) exceed its long term liabilities ($15.7M).
Debt to Equity History and Analysis
Debt Level: LOGC has more cash than its total debt.
Reducing Debt: Insufficient data to determine if LOGC's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LOGC has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: LOGC has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 27% each year.
What is LogicBio Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate LOGC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate LOGC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if LOGC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LOGC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of LOGC's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Fred Chereau (54 yo)
Mr. Frederic Chereau, also known as Fred, M.B.A., is the President and Chief Executive Officer of LogicBio Therapeutics, Inc. since April 2016 and serves as its Director. He serves as Member of Supervisory...
CEO Compensation Analysis
Compensation vs Market: Fred's total compensation ($USD1.86M) is above average for companies of similar size in the US market ($USD584.00K).
Compensation vs Earnings: Fred's compensation has increased whilst the company is unprofitable.
Experienced Management: LOGC's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Experienced Board: LOGC's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.7%.
LogicBio Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: LogicBio Therapeutics, Inc.
- Ticker: LOGC
- Exchange: NasdaqGM
- Founded: 2014
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$56.027m
- Shares outstanding: 32.96m
- Website: https://www.logicbio.com
Number of Employees
- LogicBio Therapeutics, Inc.
- 65 Hayden Avenue
- 2nd Floor
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/23 23:16|
|End of Day Share Price||2022/01/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.